Close Menu

Inostics

NEW YORK (GenomeWeb) — In a deal signed ceremoniously at the American Society of Clinical Oncology meeting earlier this week in Chicago, Merck and Sysmex Inostics will collaborate to develop and commercialize a kit to assay RAS mutations in circulating tumor DNA.

When Japan's Sysmex disclosed two weeks ago that it had acquired molecular diagnostics services firm Inostics and flow cytometry specialist Partec, it noted that the purchases were designed to aid its foray into personalized medicine and companion diagnostics.

Japanese in vitro diagnostics firm Sysmex said this week that it has acquired a pair of German companies — molecular diagnostics services firm Inostics and flow cytometry specialist Partec — in a bid to bolster its personalized medicine and companion diagnostics development business.

This story has been updated from a previous version to incorporate information about Sysmex's acquisition of Partec.

Inostics said this week that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBEAM tumor mutation test.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.

Becton Dickinson said this week that it has received clearance from the US Food and Drug Administration to market the BD Max Cdiff assay.

Following last month's publication of a study that suggested the Papanicolaou test, or Pap smear, could potentially be repurposed as a sequencing-based screening test for endometrial and ovarian cancer, the authors are now working on validating the results, hoping to develop a ro

Two studies published earlier this month in Nature have demonstrated how Inostics' BEAMing digital PCR/flow cytometry technology can be used to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure is observed.

By Ben Butkus
German molecular diagnostic services company Inostics is currently beta-testing its first assay kits featuring its BEAMing digital PCR technology, company officials said recently.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.